Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Disc Medicine (IRON)
Confident Investing Starts Here:
Nurix Therapeutics (NRIX)
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics, with a price target of $25.00. The company's shares closed last Thursday at $11.96, close to its 52-week low of $11.90.
According to TipRanks.com, Archila is a 5-star analyst with an average return of 9.3% and a 50.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Monte Rosa Therapeutics, and Apellis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $29.43 average price target, a 137.9% upside from current levels. In a report issued on June 2, Needham also maintained a Buy rating on the stock with a $27.00 price target.
Disc Medicine (IRON)
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Disc Medicine. The company's shares closed last Thursday at $52.71.
According to TipRanks.com, Bancroft is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 37.1% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Whitehawk Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $99.10 average price target, implying a 95.9% upside from current levels. In a report issued on June 10, Raymond James also initiated coverage with a Buy rating on the stock with a $89.00 price target.
Silence Therapeutics (SLN)
In a report released today, Myles Minter from William Blair reiterated a Buy rating on Silence Therapeutics. The company's shares closed last Thursday at $5.59, close to its 52-week low of $3.19.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 6.9% and a 47.1% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Financial Companies: Robinhood (HOOD) and Coinbase Global (COIN)
Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Robinhood (HOOD – Research Report) and Coinbase Global (COIN – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Robinhood (HOOD) In a report issued on August 1, Craig Siegenthaler from Bank of America Securities maintained a Buy rating on Robinhood, with a price target of $119.00. The company's shares closed last Friday at $99.90. According to Siegenthaler is a top 100 analyst with an average return of 18.8% and a 64.0% success rate. Siegenthaler covers the Financial sector, focusing on stocks such as Intercontinental Exchange, Apollo Global Management, and Victory Capital Holdings. Robinhood has an analyst consensus of Moderate Buy, with a price target consensus of $108.06, which is a 10.5% upside from current levels. In a report issued on July 17, TR | OpenAI – 4o also upgraded the stock to Buy with a $118.00 price target. Coinbase Global (COIN) Coinbase Global received a Sell rating and a $248.00 price target from Compass Point analyst Ed Engel today. The company's shares closed last Friday at $314.69. Engel has an average return of 0.8% when recommending Coinbase Global. According to Engel is ranked #8697 out of 9897 analysts. Currently, the analyst consensus on Coinbase Global is a Moderate Buy with an average price target of $387.97, implying a 15.8% upside from current levels. In a report issued on August 1, H.C. Wainwright also reiterated a Sell rating on the stock with a $300.00 price target.
Business Insider
2 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Resmed (RMD) and Envista Holdings (NVST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch + Lomb Corporation (BLCO – Research Report), Resmed (RMD – Research Report) and Envista Holdings (NVST – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch + Lomb Corporation (BLCO) J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Bausch + Lomb Corporation on July 30 and set a price target of $13.00. The company's shares closed last Friday at $13.50, close to its 52-week low of $13.16. According to Marcus is a 4-star analyst with an average return of 8.8% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Merit Medical Systems. Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $14.69, implying an 8.2% upside from current levels. In a report issued on July 30, Needham also maintained a Hold rating on the stock. Resmed (RMD) J.P. Morgan analyst David Low maintained a Buy rating on Resmed yesterday and set a price target of $310.00. The company's shares closed last Friday at $279.20. According to Low is a 4-star analyst with an average return of 7.6% and a 57.0% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Cochlear, and CSL. Resmed has an analyst consensus of Strong Buy, with a price target consensus of $295.40, implying a 4.8% upside from current levels. In a report released yesterday, KeyBanc also maintained a Buy rating on the stock with a $298.00 price target. Envista Holdings (NVST) J.P. Morgan analyst Rachel Vatnsdal maintained a Hold rating on Envista Holdings yesterday and set a price target of $20.00. The company's shares closed last Friday at $20.83. According to Vatnsdal is a 1-star analyst with an average return of -1.2% and a 39.3% success rate. Vatnsdal covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Twist Bioscience, and Myriad Genetics. Envista Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $22.17, which is a 9.6% upside from current levels. In a report issued on July 29, UBS also maintained a Hold rating on the stock with a $22.00 price target.
Business Insider
2 days ago
- Business Insider
Analysts' Opinions Are Mixed on These Financial Stocks: Lendingtree (TREE), Flagstar Financial (FLG) and Houlihan Lokey (HLI)
Analysts have been eager to weigh in on the Financial sector with new ratings on Lendingtree (TREE – Research Report), Flagstar Financial (FLG – Research Report) and Houlihan Lokey (HLI – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lendingtree (TREE) J.P. Morgan analyst Melissa Wedel maintained a Buy rating on Lendingtree yesterday and set a price target of $66.00. The company's shares closed last Friday at $49.47. According to Wedel is a 4-star analyst with an average return of 10.5% and a 67.1% success rate. Wedel covers the Financial sector, focusing on stocks such as MidCap Financial Investment Corporation, Blackstone Secured Lending Fund, and Sixth Street Specialty Lending. Lendingtree has an analyst consensus of Strong Buy, with a price target consensus of $66.40, implying a 37.3% upside from current levels. In a report issued on July 24, KBW also maintained a Buy rating on the stock with a $66.00 price target. Flagstar Financial (FLG) J.P. Morgan analyst Anthony Elian maintained a Hold rating on Flagstar Financial on July 31 and set a price target of $12.50. The company's shares closed last Friday at $11.20. According to Elian has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.7% and a 32.0% success rate. Elian covers the Financial sector, focusing on stocks such as Zions Bancorporation National Association, Pinnacle Financial Partners, and First Citizens BancShares. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Flagstar Financial with a $13.45 average price target, representing a 19.6% upside. In a report issued on July 28, TR | OpenAI – 4o also initiated coverage with a Hold rating on the stock with a $11.50 price target. Houlihan Lokey (HLI) J.P. Morgan analyst Ken Worthington maintained a Hold rating on Houlihan Lokey on July 30 and set a price target of $197.00. The company's shares closed last Friday at $189.79, close to its 52-week high of $192.10. According to Worthington is a 4-star analyst with an average return of 2.9% and a 52.9% success rate. Worthington covers the Financial sector, focusing on stocks such as Intercontinental Exchange, Apollo Global Management, and Victory Capital Holdings. Houlihan Lokey has an analyst consensus of Moderate Buy, with a price target consensus of $197.17.
